Drugs and Medicine

Cytarabine

Question: How could the hemogloblin count go up during chemotherapy? I got some results that show that as a patient was getting chemotherapy (Daunorubicin and Cytarabine), the amoutn of white blood cells and platelets went down, but the mass of hemogloblin per Liter went up. Anybody able to explain this?

Answer: Possible that the patient being treated with a red blood cell booster drug like Arnasep or Procrit? (i.e. EPO.) My hemoglobin was ridiculously low at diagnosis for advanced stage Hodgkin's Disease -- it was actually around 7.0. So I started getting Arnasep shots and it increased despite the chemo. Once it hit 11.0, the Arnasep was discontinued, but my hemoglobin still kept climbing despite the chemo. If the patient was like me and had a heavy disease burden, perhaps knocking back the cancer is allowing the body and bone marrow to function better. Would also consider dehydration -- makes the blood more concentrated which can make the hemoglobin level seem higher.

 


Cytarabine Related Products and News

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2 ...

MarketWatch (press release)
"We are pleased to have completed enrollment of the Phase 2 portion of sapacitabine vs. low-dose cytarabine in elderly patients with AML or high risk MDS," said Professor Alan K. Burnett, MD, Department of Haematology, University of Cardiff and study ...
 

Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and ...

MarketWatch (press release)
In March, patient dosing began in the Cardiff University sponsored Phase 2/3 randomized, controlled, multicenter LI-1 Trial, which is evaluating novel treatment regimens, including two regimens containing vosaroxin, against low dose cytarabine in ...
 

Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and ...

GlobeNewsWire (press release)
In March, patient dosing began in the Cardiff University sponsored Phase 2/3 randomized, controlled, multicenter LI-1 Trial, which is evaluating novel treatment regimens, including two regimens containing vosaroxin, against low dose cytarabine in ...
 

Cyclacel to Report New Sapacitabine Clinical Data at the American Society of ...

MarketWatch (press release)
... with seliciclib in patients with advanced solid tumors and an investigator-led, Phase 2/3 study comparing sapacitabine to low dose cytarabine as front-line treatment of elderly patients with AML or high risk MDS unfit for intensive chemotherapy.
 

An ASCO Bio-Pharma Catalyst Trade With A Promising Leukemia Drug

Seeking Alpha
We are currently evaluating vosaroxin in our Phase III VALOR trial, a multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
 

Sunesis Pharmaceuticals Receives European Orphan Drug Designation for ...

MarketWatch (press release)
Sunesis is currently enrolling patients in its VALOR trial, a Phase 3, multinational, randomized, double-blind, placebo-controlled, pivotal clinical trial of vosaroxin in combination with cytarabine in first relapsed or refractory acute myeloid ...
 

Thalidomide-Trisenox Combination May Be Effective And Safe In MDS Patients

The MDS Beacon
Trisenox has recently been tested in combination with cytarabine (Cytosar-U). The study results showed, however, that Trisenox did not improve upon results found with cytarabine alone (see related Beacon news). According to the Chinese investigators, ...
 

Call for New Treatment Approaches in Acute Myeloid Leukemia

Cancer Network
[2] The 652 patients in the trial received one of three induction regimens: DA (daunorubicin plus cytarabine), DAC (DA plus cladribine), or DAF (DA plus fludarabine). All patients received the same post-remission treatment.
 

Sunesis Pharmaceuticals Receives European Orphan Drug Designation for ...

PharmaLive.com (press release)
Sunesis is currently enrolling patients in its VALOR trial, a Phase 3, multinational, randomized, double-blind, placebo-controlled, pivotal clinical trial of vosaroxin in combination with cytarabine in first relapsed or refractory acute myeloid ...
 

EC grants orphan drug designation to Sunesis Vosaroxin drug

Pharmaceutical Business Review
Currently, the company is enrolling patients in its Phase 3 multinational randomized double-blind placebo-controlled pivotal VALOR study of Vosaroxin in combination with cytarabine. The trial is expected to enroll 450 evaluable patients who will be ...